Friday, October 28, 2016Taking a break for a moment from the Q3 earnings deluge — which continues, and will remain heavy next week and beyond — to report on our first read of Q3 Gross Domestic Product (GDP). At 2.9%, we are seeing a snap-back from below-trend growth earlier in the year, heating up higher than expectations. This is the highest read on GDP in two years.
Analysts had been starting to look at 3% growth in 2016 as something of a pipe dream lately, with the final read on Q2 GDP at a relatively paltry 1.4%. In fact, core GDP quarter over quarter is actually down from Q2 — 1.7% versus 1.8% last time.
So what accounts for this upswing? Exports are +10%. As economies in both developing and developed nations gain sounder footing, demand for U.S. products has grown, even with a stronger dollar in play. Where we see negative numbers are in things like equipment (-2.7%), which appears to have been affected by persistently low oil prices.
As a result, we see the 10-year bond yield inching upward to 1.8% — still way below historic averages, but higher than the 1.7% it had been stuck at all summer. As we continue to see economic metrics strengthening, we will keep our eye on things like the 10-year a bit more closely.
Q3 Earnings Plod Along
Exxon Mobil (XOM - Free Report) posted mixed Q3 earnings results — 63 cents per share beat the 60 cents we had expected, though revenues of $58.68 billion in the quarter was light the $60.56 billion in the Zacks consensus. The company’s barrels of oil equivalent produced per day was down 2.7%.
AutoNation (AN - Free Report) also missed top-line expectations, and came in 10 cents light on the bottom line, as well. $1.05 per share marks the second negative earnings surprise in the past four quarters. Takeda airbag problems that have hit the company’s supply chain persist.
Humira manufacturer AbbVie (ABBV - Free Report) just met earnings estimates of $1.21 per share while falling short of the $6.55 billion in sales, reporting $6.43 billion. The company did tighten its full-year earnings guidance to $4.80-4.82 per share.
Has anyone outperformed this morning? Sure — Mastercard (MA - Free Report) put up $1.08 per share, outpacing the 98 cents expected. Sales of $2.9 billion in the quarter topped the $2.74 billion in the Zacks consensus estimate.
Mark Vickery
Senior Editor
Click here to follow this author>>
Friday, October 28, 2016
Taking a break for a moment from the Q3 earnings deluge — which continues, and will remain heavy next week and beyond — to report on our first read of Q3 Gross Domestic Product (GDP). At 2.9%, we are seeing a snap-back from below-trend growth earlier in the year, heating up higher than expectations. This is the highest read on GDP in two years.
Analysts had been starting to look at 3% growth in 2016 as something of a pipe dream lately, with the final read on Q2 GDP at a relatively paltry 1.4%. In fact, core GDP quarter over quarter is actually down from Q2 — 1.7% versus 1.8% last time.
So what accounts for this upswing? Exports are +10%. As economies in both developing and developed nations gain sounder footing, demand for U.S. products has grown, even with a stronger dollar in play. Where we see negative numbers are in things like equipment (-2.7%), which appears to have been affected by persistently low oil prices.
As a result, we see the 10-year bond yield inching upward to 1.8% — still way below historic averages, but higher than the 1.7% it had been stuck at all summer. As we continue to see economic metrics strengthening, we will keep our eye on things like the 10-year a bit more closely.
Q3 Earnings Plod Along
Exxon Mobil (XOM - Free Report) posted mixed Q3 earnings results — 63 cents per share beat the 60 cents we had expected, though revenues of $58.68 billion in the quarter was light the $60.56 billion in the Zacks consensus. The company’s barrels of oil equivalent produced per day was down 2.7%.
AutoNation (AN - Free Report) also missed top-line expectations, and came in 10 cents light on the bottom line, as well. $1.05 per share marks the second negative earnings surprise in the past four quarters. Takeda airbag problems that have hit the company’s supply chain persist.
Humira manufacturer AbbVie (ABBV - Free Report) just met earnings estimates of $1.21 per share while falling short of the $6.55 billion in sales, reporting $6.43 billion. The company did tighten its full-year earnings guidance to $4.80-4.82 per share.
Has anyone outperformed this morning? Sure — Mastercard (MA - Free Report) put up $1.08 per share, outpacing the 98 cents expected. Sales of $2.9 billion in the quarter topped the $2.74 billion in the Zacks consensus estimate.
Mark Vickery
Senior Editor
Click here to follow this author>>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on MA - FREE
Get the latest research report on XOM - FREE
Get the latest research report on AN - FREE
Get the latest research report on ABBV - FREE